Regulus Therapeutics Inc. (NASDAQ:RGLS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

A number of other research analysts have also recently commented on RGLS. Chardan Capital cut their price target on shares of Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating on the stock in a report on Tuesday, June 13th. BMO Capital Markets set a $1.00 price target on shares of Regulus Therapeutics and gave the stock a “hold” rating in a report on Monday, June 12th. Wedbush restated an “ourperform” rating and issued a $6.00 price target on shares of Regulus Therapeutics in a report on Tuesday, June 13th. Finally, ValuEngine cut shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $3.92.

Shares of Regulus Therapeutics (NASDAQ:RGLS) opened at 0.946 on Wednesday. Regulus Therapeutics has a 52-week low of $0.86 and a 52-week high of $4.25. The stock’s market capitalization is $50.31 million. The stock has a 50 day moving average of $1.11 and a 200 day moving average of $1.45.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/19/regulus-therapeutics-inc-nasdaqrgls-cut-to-hold-at-zacks-investment-research.html.

Several hedge funds have recently added to or reduced their stakes in the stock. First American Bank purchased a new position in Regulus Therapeutics during the fourth quarter worth approximately $281,000. Oxford Asset Management purchased a new position in Regulus Therapeutics during the fourth quarter worth approximately $2,335,000. Tudor Investment Corp Et Al purchased a new position in Regulus Therapeutics during the fourth quarter worth approximately $105,000. Wells Fargo & Company MN increased its position in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 93,295 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Regulus Therapeutics by 3.8% in the first quarter. Goldman Sachs Group Inc. now owns 774,070 shares of the biopharmaceutical company’s stock worth $5,364,000 after buying an additional 28,265 shares during the period. 38.56% of the stock is owned by institutional investors and hedge funds.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.